All In Biotech

Drug Trial Radar · NCT07446309

Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults

A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Continuous Intravenous Infusion of HRS-9190 Versus Cisatracurium for Maintaining Neuromuscular Blockade During General Anesthesia in Adults Undergoing Elective Surgery.

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Apr 10, 2026

Primary completion

Jul 14, 2026

Study completion Jul 29, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium. The primary objective is to measure the duration from cessation of the study drug infusion until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include onset time, duration of action, total time of adequate muscle relaxation during surgery, and neuromuscular recovery pattern.. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.

Conditions

  • Neuromuscular Blockade

Interventions

  • HRS-9190; under Inhalational AnesthesiaDrug

    HRS-9190; under Inhalational Anesthesia

  • HRS-9190; under Intravenous AnesthesiaDrug

    HRS-9190; under Intravenous Anesthesia

  • Cisatracurium (under Inhalational Anesthesia).Drug

    Cisatracurium (under Inhalational Anesthesia).

  • Cisatracurium (under Intravenous Anesthesia)Drug

    Cisatracurium (under Intravenous Anesthesia)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from Cessation of Infusion to Recovery of TOFr to 0.9Time frame: From the end of continuous infusion of the study drug until the time point when TOFr ≥ 90% is first achieved, assessed intraoperatively and in the immediate postoperative period, up to 2 hours

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • ZhongShan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial People'S Hospital

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.